PREVENT.

REDUCE.

SOLVE.

OTOLITH LABS RECEIVES BREAKTHROUGH
DESIGNATION FROM THE FDA.

PREVENT.

REDUCE.

SOLVE.

OTOLITH LABS RECEIVES BREAKTHROUGH
DESIGNATION FROM THE FDA.

Upcoming At-home Vertigo Study

In early 2022 Otolith Labs will begin enrollment for an at-home study of a possible treatment for vertigo. Enrollment will be limited and there will be no cost to you. All information will be kept confidential and we will not attempt to sell you anything. 

Otolith Labs is developing a new head-worn wearable device for the treatment of vertigo. The device is safe and simple to use. 

Tested By:

Latest News

Otolith Receives Breakthrough Device Designation from FDA

Otolith Receives Breakthrough Device Designation from FDA

Otolith Labs announces closing of $3.3 Million in seed funding, as well as receiving “Breakthrough Device” Designation from FDA.

MedTech Innovator Selects Otolith Labs in Top 50 Medtech Startups

MedTech Innovator Selects Otolith Labs in Top 50 Medtech Startups

MedTech innovator unveils top 50 medtech startups selected for Annual showcase and accelerator, which includes Otolith Labs.

NASA iTech 2020 Cycle 1 Winner

NASA iTech 2020 Cycle 1 Winner

Through NASA’s iTech initiative, the agency discovers and assesses technologies that could help it accomplish future missions. Otolith Labs was one of the three winning teams in 2020.

Increased Bone Conducted Vibration Reduces Motion Sickness

Increased Bone Conducted Vibration Reduces Motion Sickness

Results from a study testing bone conductive vibrations proved the device decreases nausea from motion sickness.

© 2021 Otolith Labs, Inc.